Dashboard
Manage Tickers

ATHAAthira Pharma, Inc.

Nasdaq athira.com


$ 3.33 $ 0.21 (6.75 %)    

Friday, 23-Aug-2024 15:59:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 479.76 $ 5.15 (1.08 %)
DIA $ 411.97 $ 4.35 (1.07 %)
SPY $ 562.00 $ 5.91 (1.06 %)
TLT $ 98.37 $ 0.64 (0.65 %)
GLD $ 231.99 $ 2.65 (1.16 %)
$ 3.32
$ 3.32 x 100
$ 3.33 x 200
-- - --
$ 1.33 - $ 4.30
169,047
na
127.62M
$ 1.02
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 02-22-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-23-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-28-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-25-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

rodman--renshaw-initiates-coverage-on-athira-pharma-with-buy-rating-announces-price-target-of-22
Rodman & Renshaw Initiates Coverage On Ath...
08/19/2024 14:37:25

Rodman & Renshaw analyst Elemer Piros initiates coverage on Athira Pharma (NASDAQ:ATHA) with a Buy rating and announces ...

athira-pharma-q2-eps-070-beats-074-estimate
Athira Pharma Q2 EPS $(0.70) Beats $(0.74)...
08/01/2024 20:48:16

Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.74)...

athira-pharma-to-present-preclinical-data-demonstrating-new-insights-into-the-mechanism-by-which-fosgonimeton-protects-neurons-from-alzheimers-disease-related-pathology-at-aaic-2024
Athira Pharma To Present Preclinical Data ...
07/31/2024 12:28:34

Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms t...

jmp-securities-reiterates-market-outperform-on-athira-pharma-maintains-19-price-target
JMP Securities Reiterates Market Outperfor...
06/20/2024 14:59:49

JMP Securities analyst Jason Butler reiterates Athira Pharma (NASDAQ:ATHA) with a Market Outperform and maintains $19 price ...

athira-pharma-advances-als-drug-with-successful-phase-1-trial-in-healthy-volunteers
Athira Pharma Advances ALS Drug with Succe...
06/11/2024 11:03:32

BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical co...

athira-pharma-to-be-issued-us-patent-for-methods-of-treating-parkinsons-disease-and-lewy-body-disease
Athira Pharma To Be Issued US Patent For "...
06/03/2024 19:34:42

jmp-securities-reiterates-market-outperform-on-athira-pharma-maintains-19-price-target
JMP Securities Reiterates Market Outperfor...
05/16/2024 16:53:32

JMP Securities analyst Jason Butler reiterates Athira Pharma (NASDAQ:ATHA) with a Market Outperform and maintains $19 price ...

athira-pharma-q1-2024-gaap-eps-069-beats-078-estimate
Athira Pharma Q1 2024 GAAP EPS $(0.69) Bea...
05/15/2024 20:40:48

Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.78)...

athira-pharma-announces-publication-of-preclinical-data-highlighting-fosgonimeton-treatment-in-models-of-alzheimers-disease
Athira Pharma Announces Publication of Pre...
04/11/2024 11:09:42

Key findings reported in the study publication regarding fosgonimeton in preclinical models of Alzheimer's disease include:...

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
03/27/2024 20:31:13

athira-pharma-presents-clinical-and-preclinical-data-supporting-therapeutic-potential-of-fosgonimeton-in-alzheimers-and-parkinsons-diseases-at-adpd-2024-international-conference
Athira Pharma Presents Clinical and Precli...
03/08/2024 12:01:15

Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to res...

athira-pharma-announces-publication-in-frontiers-in-neuroscience-highlighting-therapeutic-potential-of-ath-1105-in-amyotrophic-lateral-sclerosis
Athira Pharma Announces Publication In Fro...
02/08/2024 21:22:59

Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to res...

athira-pharma-provides-2024-clinical-pipeline-outlook-topline-data-from-phase-23-lift-ad-trial-of-fosgonimeton-for-mild-to-moderate-alzheimers-disease-expected-in-2h-of-2024
Athira Pharma Provides 2024 Clinical Pipel...
01/08/2024 13:23:23

Plans To Initiate First-in-human Studies Of ATH-1105 For Amyotrophic Lateral Sclerosis In 1H Of 2024  

athira-pharma-has-completed-enrollment-in-the-phase-23-lift-ad-trial-of-fosgonimeton-as-a-potential-treatment-for-mild-to-moderate-alzheimers-disease-topline-data-is-on-track-for-2h-of-2024
Athira Pharma Has Completed Enrollment In ...
01/03/2024 12:08:27

15m-bet-on-this-healthcare-stock-check-out-these-4-penny-stocks-insiders-are-aggressively-buying
$1.5M Bet On This Healthcare Stock? Check ...
01/02/2024 11:40:52

The Dow Jones index closed lower by around 20 points on Friday. When insiders purchase or sell shares, it indicates their confi...

athira-pharma-announces-results-from-shape-phase-2-clinical-trial-of-fosgonimeton-for-the-treatment-of-parkinsons-disease-dementia-and-dementia-with-lewy-bodies
Athira Pharma Announces Results from SHAPE...
12/12/2023 12:02:23

 Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to re...

athira-pharma-announced-that-a-symposium-presentation-highlighting-data-from-preclinical-studies-of-ath-1105-for-amyotrophic-lateral-sclerosis-will-be-delivered-at-the-upcoming-motor-neurone-disease-association-international-symposium
Athira Pharma Announced That A Symposium P...
11/28/2023 12:16:05

athira-pharma-presents-preclinical-data-highlighting-fosgonimetons-neuroprotective-effects-against-amyloid--induced-pathological-alterations-and-neuroinflammation-in-models-of-alzheimers-disease
Athira Pharma Presents Preclinical Data Hi...
11/15/2023 13:18:16

Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to res...

athira-pharma-q3-eps-087-misses-081-estimate
Athira Pharma Q3 EPS $(0.87) Misses $(0.81...
11/09/2023 22:11:20

Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.8...

athira-pharma-presents-preclinical-data-further-supporting-the-therapeutic-potential-of-ath-1105-in-amyotrophic-lateral-sclerosis
Athira Pharma Presents Preclinical Data Fu...
10/05/2023 20:32:19

New results support the neuroprotective effects of ATH-1105 in preclinical models of ALS, as indicated by consistent reduction ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION